FDA has issued a list of planned draft and final guidance documents for release throughout 2012. There are approximately 50 such guidances planned.
FDA has issued a list of planned draft and final guidance documents for release throughout 2012. There are about 50 such guidances planned. Below are a few highlights for the drug-manufacturing space.
In biopharmaceutics and biosimilarity:
Food-Effect Bioavailability and Fed Bioequivalence Studies-Bioavailability and Bioequivalence Studies for Orally Administered Drug Products Submitted in New Drug Applications General Consideration
Advertisement
Scientific Considerations in Demonstrating Biosimilarity To a Reference Product (draft already issued)
Quality Considerations in Demonstrating Biosimilarity To a Reference Protein Product (draft already issued)
Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 (draft already issued)
In combination products:
Development of Drugs in Combination
In CGMPs and compliance:
Control of Highly Potent Compounds
Expiration Dating of Unit-Dose Repackaged Drugs: Compliance Policy Guide
Importation of Active Pharmaceutical Ingredients (API) for Use in Human Drugs
In labeling, packaging, and supply chain:
Naming, Labeling, and Packaging Practices to Reduce Medication Errors
Securing the Drug Supply Chain-Standards for Tracking and Tracing Prescription Drug Packages
Drug Names and Dosage Forms
Organ-Specific Warnings: Internal Analgesic, Antipyretic and Antirheumatic Drug Products for Over-the-Counter Human Use-Labeling of Products That Contain Acetaminophen
Pediatric Information: Incorporating into Human Prescription Drug and Biological Products Labeling
In regulatory filings (electronic):
Providing Regulatory Submissions in Electronic Format – General Considerations
Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications
Providing Regulatory Submissions in Electronic Format – Study Data
Providing Regulatory Submissions in Electronic Format – Standardized Study Data